|
[1]SHIRATORI Y, IMAZEKI F, MORIYAMA M, et al.Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy[J].Ann Intern Med, 2000, 132 (7) :517-524.
|
|
[2]YOSHIDA H, SHIRATORI Y, MORIYAMA M, et al.Interferon therapy reduces the risk for hepatocellular carcinoma:national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan.IHIT Study Group.Inhibition of Hepatocarcinogenesis by Interferon Therapy[J].Ann Intern Med, 1999, 131 (3) :1741-1781.
|
|
[3]SHIRATORI Y, SHIINA S, TERATANI T, et al.Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus[J].Ann Intern Med, 2003, 138 (4) :299-306.
|
|
[4]YOSHIDA H, ARAKAWA Y, SATA M, et al.Interferon therapy prolonged life expectancy among chronic hepatitis C patients[J].Gastroenterology, 2002, 123 (2) :483-491.
|
|
[5]YU ML, CHUANG WL.Treatment of chronic hepatitis C in Asia:when east meets west[J].J Gastroenterol Hepatol, 2009, 24 (3) :336-345.
|
|
[6]PAWLOTSKY JM, FELD JJ, ZEUZEM S, et al.From non-A, non-B hepatitis to hepatitis C virus cure[J].J Hepatol, 2015, 62 (1 Suppl) :s87-s99.
|
|
[7]MORGAN TR, GHANY MG, KIM HY, et al.Outcome of sustained virological responders with histologically advanced chronic hepatitis C[J].Hepatology, 2010, 52 (3) :833-844.
|
|
[8]LI DK, CHUNG RT.Impact of hepatitis C virus eradication on hepatocellular carcinogenesis[J].Cancer, 2015, 121 (17) :2874-2882.
|
|
[9]CHANG KC, HUNG CH, LU SN, et al.A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy[J].J Antimicrob Chemother, 2012, 67 (11) :2766-2772.
|
|
[10]MAURO E, CRESPO G, MONTIRONI C, et al.Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after SVR in recurrent hepatitis C[J].Hepatology, 2017.[Epub ahead of print]
|
|
[11]WANG JH, YEN YH, YAO CC, et al.Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy[J].Liver Int, 2016, 36 (12) :1793-1799.
|
|
[12]XING J, SPRADLING PR, MOORMAN AC, et al.Chronic Hepatitis Cohort Study (CHe CS) Investigators.A point system to forecast hepatocellular carcinoma risk before and after treatment among persons with chronic hepatitis C[J].Dig Dis Sci, 2017, 62 (11) :3221-3234.
|
|
[13]UMEHARA Y, HAGIWARA S, NISHIDA N, et al.Hepatocarcinogenesis is associated with serum albumin levels after sustained virological responses with interferon-based therapy in patients with hepatitis C[J].Dig Dis, 2017, 35 (6) :548-555.
|
|
[14]NAHON P, BOURCIER V, LAYESE R, et al.Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications[J].Gastroenterology, 2017, 152 (1) :142-156.e2.
|
DownLoad: